Patents by Inventor Zhifang Cao

Zhifang Cao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for treating inflammatory bowel disease
    Patent number: 11382908
    Abstract: Disclosed herein are compounds for the treatment of inflammatory bowel disease. Additionally, provided herein are compositions and methods for using these compounds and compositions in the treatment of inflammatory bowel disease in a subject.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: July 12, 2022
    Assignees: The Broad Institute, Inc., The General Hospital Corporation, President and Fellows of Harvard College
    Inventors: Elizaveta Leshchiner, Zhifang Cao, Jason Rush, Michael Durney, Alykhan Shamji, Daniel Graham, Stuart L. Schreiber, Ramnik Xavier
  • COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE
    Publication number: 20200268736
    Abstract: Disclosed herein are compounds for the treatment of inflammatory bowel disease. Additionally, provided herein are compositions and methods for using these compounds and compositions in the treatment of inflammatory bowel disease in a subject.
    Type: Application
    Filed: September 26, 2018
    Publication date: August 27, 2020
    Inventors: Elizaveta Leshchiner, Zhifang Cao, Jason Rush, Michael Durney, Alykhan Shamji, Daniel Graham, Stuart L. Schreiber, Ramnik Xavier
  • Purified recombinant batroxobin with high specific activity
    Patent number: 7939067
    Abstract: A purified recombinant batroxobin with high specific activity, which has the following properties: (a) the batroxobin has a molecular weight of 29-32 kDa; (b) at least 90% of the batroxobin have 6 pairs of disulfide bonds which correctly match at Cys7-Cys139, Cys26-Cys42, Cys74-Cys230, Cys118-Cys184, Cys150-Cys163 and Cysl174-Cys199; (c) positions 146 and 225 in SEQ ID NO:1 are modified as N-glycosylation; and (d) the specific activity of the batroxobin is equal to or greater than 1500 KU/mg protein.
    Type: Grant
    Filed: September 28, 2009
    Date of Patent: May 10, 2011
    Assignee: Shanghai Wanxing Biopharmaceuticals, Co., Ltd.
    Inventors: Xiudong Huang, Peixin Chen, Xuegong Pan, Qiang Wang, Zhifang Cao